Brighter’s diabetes management devices Actiste® and Actiste® Mini receives market approval in Thailand
Brighter AB (publ) is proud to announce that the Actiste® device and the newly developed Actiste® Mini device have received market approval from the Thai FDA, which is a prerequisite to start importing and marketing the products. A cellular transmission approval process, which is a requirement for activation and use of the products, is under way. Further information about Brighter’s commercial plan and strategy for Thailand will follow during the spring. “We are very pleased to have reached another significant milestone in the commercialization of the Actiste portfolio. This time in